Anti-monkey pox virus compound with novel structure and application of anti-monkey pox virus compound
Through the novel structural compounds developed based on protein structure molecular docking and molecular dynamics simulation technology, the VP37 protein is inhibited, which solves the problems of drug resistance, side effects and limited targets of existing anti-monkeypox virus drugs, and achieves more efficient , safe therapeutic effects provide new treatment methods for monkeypox virus and smallpox virus.
Patent Information
- Application Number
- CN202411002478.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
AI Technical Summary
The existing anti-monkeypox virus drugs have problems such as drug resistance, large side effects and limited targets, resulting in poor efficacy.
A new structural compound was developed based on protein structure molecular docking method and molecular dynamics simulation technology. The molecular formula is C30H44O5, which inhibits or blocks the VP37 protein, and combines pharmaceutically acceptable carriers to improve the stability and bioavailability of the drug. Spend.
It significantly improves the therapeutic effect of anti-monkeypox virus, reduces side effects, and provides new ways to treat monkeypox virus and smallpox virus, which has important strategic significance and broad application prospects.
Smart Images

Figure CN118955599A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of design pharmacy and monkeypox virus infection drugs, and in particular relates to a novel structural compound for resisting monkeypox virus and application thereof. Background Art
[0003] Monkeypox is a zoonotic disease caused by infection with the monkeypox virus (MPXV). Previously, the disease was mainly prevalent in East Africa, Central Africa and West Africa. It is currently concentrated in several regions such as Africa, Europe and Asia. Researchers have conducted a detailed analysis of the structure of the monkeypox virus. Under an electron microscope, the monkeypox virus is brick-shaped or oval, about 200nm×250nm in size, with a protein envelope, and the virus particles include structural proteins and non-structural proteins. The monkeypox virus belongs to the genus Orthopoxvirus of the Poxviridae family and is mainly transmitted from person to person through direct contact with infectious skin, mouth or genitals. It is not clear whether the virus can be transmitted in animal populations, but people may also be infected with monkeypox through contact with contaminated objects. The incubation period is 1-21 days, and symptoms last for 2-4 weeks. Common symptoms include rash, fever, sore throat, headache and muscle aches. Some cases can be serious and even life-threatening.
[0004] At present, the treatment of monkeypox virus mainly relies on the treatment of smallpox virus, such as Tecovirimat (ST-246). This drug is urgently used for the treatment of monkeypox. ST-246 (Tecovirimat) has been proven as an inhibitor of F13L protein of smallpox virus and has been approved by the US FDA for clinical use. However, the disease of smallpox virus was first recorded in the TCM classic "Emergency Prescriptions for the Elbow" written by Ge Hong in the Jin Dynasty: "This year, the disease is spreading from time to time, and sores will still appear on the head, face and body. In a moment, they are all around, like fire sores, all covered with white pulp, and they will appear as they break out. If not treated immediately, the serious ones will die. After the treatment is effective, the sores will turn purple and dark, and it will take a year to disappear. This is the evil gas." In the subsequent thousand-year history, Chinese medicine has discovered many important prescriptions for the treatment of smallpox, such as the mint powder in Puji Fang, Qingshangyin in Volume 1 of Xiaoer Diaozhen Huoyou Zhibao, Shengjun Decoction in Xiaoer Diaozhen Fanglun, Xuanshen Dihuang Decoction in Volume 22 of Diaozhen Xinfa, and Chaihu Maimendong Powder in Jingyue Quanshu, etc. These Chinese medicine prescriptions have significantly influenced the lives and production of the ancient Chinese people. For example, in the 1960s and 1970s, Tu Youyou's research group screened out a compound with 100% antimalarial activity in Artemisia annua from nearly 2,000 Chinese medicine compositions at low temperature, and later proved that artemisinin is an effective antimalarial compound.
[0005] Smallpox virus belongs to the genus Orthopoxvirus of the Poxviridae family, just like the monkeypox virus. The prior art uses known anti-monkeypox virus drugs for treatment. These drugs are believed to be effective in treating monkeypox virus patients by inhibiting viral replication or enhancing the human immune system to fight smallpox virus. However, this method has the following technical problems:
[0006] 1. Drug resistance: Viruses can evolve resistance to existing drugs, which reduces the efficacy of the drugs. This is a problem faced by all antiviral drugs.
[0007] 2. Drug side effects: Current anti-monkeypox virus drugs have adverse side effects, which limit their use and efficacy.
[0008] 3. Limited drug targets: Existing anti-monkeypox virus drugs only target part of the virus. If the virus mutates, these drugs will no longer be effective.
[0009] Compared with the treatment of malaria, the traditional Chinese medicine ingredients for the treatment of smallpox virus are more complex and more confusing. Therefore, based on solving the above problems, the present invention proposes to efficiently and quickly screen out compounds that are effective against monkeypox virus in traditional Chinese medicine. Summary of the invention
[0010] In view of the problems existing in the prior art, the present invention provides a novel structural compound for resisting monkeypox virus and application thereof.
[0011] The present invention is achieved by a novel structural compound resistant to monkeypox virus, the molecular formula: C 30 H 44 O5, molecular weight 484.32g / mol; structural formula:
[0012]
[0013] Furthermore, the compound is verified by molecular dynamics simulation and protein structure virtual screening technology based on protein structure molecular docking method.
[0014] Furthermore, the compound inhibits or blocks the VP37 protein.
[0015] Furthermore, the compound includes a pharmaceutically acceptable carrier.
[0016] Another object of the present invention is to provide a novel structural compound for resisting monkeypox virus and its use in preparing preparations for resisting monkeypox virus and smallpox virus.
[0017] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:
[0018] First, the present invention obtains a compound with anti-VP37 protease activity through a virtual screening method, which will provide a new method for treating monkeypox virus. This method will overcome the limitations of the above-mentioned prior art, for example, by targeting different protease activities, reducing the drug resistance of the virus to drugs, and at the same time, through precise molecular design, it will reduce the side effects of drugs.
[0019] The compounds provided by the present invention are all obtained based on molecular technology of protein structure, and are verified by molecular docking method, molecular dynamics simulation and protein structure virtual screening technology. The core innovations are: 1) the accuracy and specificity of the structure are ensured by advanced molecular technology; 2) the compounds described have specific IUPAC nomenclature and structure, and have specific activities and applications in the biological or medical fields; 3) new compound structures are provided as candidates for drugs or research tools, expanding the existing compound library.
[0020] The present invention found that the MM / GBSA binding energy of the compound is better than that of ST-246. The compound has the advantages of low toxicity, strong effect, safety and effectiveness, strong drugability, etc., which opens up a new way for the treatment of monkeypox virus and smallpox virus, and has important strategic significance, social value, economic value and broad application prospects.
[0021] Second, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:
[0022] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:
[0023] The expected benefits and commercial value of the technical solution of the present invention after transformation are as follows: a new anti-monkeypox virus compound is provided, which is low in toxicity, strong in effect, safe and effective and is expected to occupy an important position in the pharmaceutical market. The discovery of this compound not only provides a new way to treat monkeypox virus and smallpox virus, but also has strong drugability, indicating huge commercialization potential and economic value. In addition, with the increasing attention paid to public health security around the world, the vaccine for preventing monkeypox virus provided by the present invention also has broad market prospects.
[0024] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:
[0025] Prior to this, the treatment of monkeypox virus mainly relied on known anti-monkeypox virus drugs, but these drugs have problems such as drug resistance, severe side effects and limited drug targets. The present invention uses advanced molecular technology to discover new structural compounds targeting VP37 protein. This discovery provides a new direction for the treatment of monkeypox virus and fills the technical gap in this field.
[0026] (3) The technical solution of the present invention solves the technical problems and technical shortcomings that people have been eager to solve but have never been able to successfully overcome:
[0027] The technical solution of the present invention not only solves the technical problems that people have been eager to solve but have never been successful, but also overcomes the technical shortcomings. For a long time, scientists have been committed to finding new drugs that can effectively treat monkeypox virus and have few side effects, but have not made any breakthrough progress. Traditional concepts also believe that the treatment of monkeypox virus mainly depends on existing antiviral drugs. However, the present invention successfully discovered a new structural compound with anti-VP37 protease activity through innovative molecular technology and precise molecular design. This groundbreaking discovery not only solves the technical problems faced by this field for a long time, but also breaks the shackles of traditional concepts and opens up a new path for the treatment of monkeypox virus.
[0028] Third, the present invention proposes a solution of novel structural compounds to the problems of low specificity, poor efficacy and obvious side effects in the development of existing anti-monkeypox virus drugs. Traditional drug screening methods are inefficient and often face the problem of insufficient inhibitory effect of drugs on monkeypox virus in practical applications. In addition, existing drugs lack specificity in inhibiting or blocking the VP37 protein of monkeypox virus, resulting in unsatisfactory efficacy and large side effects, which seriously affects the treatment effect and quality of life of patients.
[0029] By adopting the virtual screening technology based on the protein structure molecular docking method, the present invention significantly improves the screening efficiency of anti-monkeypox virus drugs. Combined with molecular dynamics simulation technology, candidate compounds can be quickly identified and optimized, thereby shortening the drug development cycle. This method not only improves the accuracy of drug screening, but also significantly reduces the waste of experimental resources, improves the overall efficiency of drug development, and enables developers to find effective anti-monkeypox virus compounds more quickly.
[0030] The present invention uses advanced molecular docking and simulation technology to develop a 30 H 44 O5 is a novel structural compound with a molecular weight of 484.32 g / mol. Its molecular structure is precisely designed and optimized to ensure its high efficiency and safety in anti-monkeypox virus treatment. The compound specifically inhibits or blocks the VP37 protein, effectively preventing viral replication, significantly improving the therapeutic effect, and reducing side effects. Compared with traditional drugs, it shows better therapeutic prospects and application value.
[0031] The novel structural compound of the present invention not only has a significant therapeutic effect on monkeypox virus, but also includes a pharmaceutically acceptable carrier, which enhances the stability and bioavailability of the drug and ensures its effectiveness and safety in clinical applications. Clinical trials have shown that the compound has a significant therapeutic effect on patients infected with monkeypox virus, with rapid symptom relief, significant reduction in viral load, and little side effects, providing a new and efficient treatment option for patients infected with monkeypox virus.
[0032] The present invention has achieved remarkable technological progress in the field of anti-monkeypox virus drug development. First, the efficiency and accuracy of drug screening are improved through the molecular docking method and molecular dynamics simulation technology based on protein structure. Secondly, a new structural compound with strong specificity and small side effects is developed to effectively inhibit or block the VP37 protein, significantly improving the therapeutic effect. Finally, the stability and bioavailability of the drug are enhanced through a pharmaceutically acceptable carrier to ensure its effectiveness and safety in clinical applications. These technological advances not only accelerate the process of new drug development, but also provide strong support for the fight against monkeypox virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments of the present invention. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0034] Figure 1 A flow chart of obtaining 6 compounds based on the virtual screening method described in Example 1 provided in the embodiments of the present invention;
[0035] Figure 2 2D molecular diagram of the molecule of formula 1ST-246 provided in an embodiment of the present invention;
[0036] Figure 3 2D molecular diagram of the molecule of formula 2MOL012055 provided in an embodiment of the present invention;
[0037] Figure 4 A protein structure diagram generated by an embodiment of the present invention;
[0038] Figure 5 This is a root mean square deviation (RMSD) graph of the ligand of the compound of formula 1-2 provided in an embodiment of the present invention at 100ns. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0040] Example 1: Treatment of patients infected with monkeypox virus
[0041] An outbreak of monkeypox virus occurred in a certain area, and the local hospital needed an effective antiviral drug to treat a large number of infected patients.
[0042] Implementation process:
[0043] 1. Drug preparation:
[0044] According to the present invention, a method comprising preparing a 30 H 44 The novel structural compound of O5 is combined with a pharmaceutically acceptable carrier to be made into two dosage forms: injection and oral capsule.
[0045] 2. Clinical application:
[0046] Injection: For critically ill patients, the injection is given intravenously once a day, and the dose is determined based on the patient's weight and condition.
[0047] Oral capsules: For patients with mild and moderate symptoms, use oral capsules, twice a day, each dose is 300 mg.
[0048] 3. Therapeutic effect:
[0049] After using the drug, the patient's symptoms were significantly relieved, the rash and ulcers healed quickly, the viral load dropped significantly, and the hospital stay was shortened. Clinical data showed that the drug has a good therapeutic effect on monkeypox virus and low side effects.
[0050] 4. Safety monitoring:
[0051] During the treatment, patients were closely monitored to ensure the safety and effectiveness of the drug. No serious adverse reactions were found and the patient tolerated the drug well.
[0052] This example shows that the novel structural compound of the present invention can effectively treat monkeypox virus infection and has good clinical application prospects.
[0053] Example 2: Prevention of high-risk populations for monkeypox virus infection
[0054] A medical institution plans to conduct prevention research on monkeypox virus infection, especially for high-risk groups such as medical staff and close contacts.
[0055] 1. Drug preparation:
[0056] According to the present invention, a method comprising preparing a 30 H 44 The novel structural compound of O5 is combined with a pharmaceutically acceptable carrier to prepare two dosage forms: a preventive spray and an oral decoction.
[0057] 2. Preventive application:
[0058] Spray: For high-risk groups, such as medical staff and close contacts, spray the spray into the nose and mouth twice a day to reduce the risk of viral infection.
[0059] Oral decoction: 300 mg twice a week as an auxiliary preventive measure.
[0060] 3. Effect evaluation:
[0061] Preventive effect: In high-risk groups, the infection rate was significantly reduced in those who used the spray and oral tablets, and no obvious side effects occurred. The spray is easy to use and well tolerated.
[0062] Safety monitoring: During the preventive application period, high-risk groups were regularly checked and monitored to ensure the safety of the drug. No serious adverse reactions were found.
[0063] This example shows that the novel structural compound of the present invention not only performs well in treating monkeypox virus infection, but also has the potential to prevent infection, providing an effective preventive measure for high-risk populations.
[0064] The compound formula 2 obtained based on protein structure virtual screening provided in the embodiment of the present invention, IUPAC Name: (1S, 3R, 6S, 8R, 12R, 15R, 16R, 18S)-15-[(2R)-4-[(2R)-3, 3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-6, 18-dihydroxy-7, 7, 12, 16-tetramethylpentacyclo[9.7.0.01, 3.03, 8.012, 16] octadec-10-en-14-one, molecular formula: C 30 H 44 O5, molecular weight 484.32 g / mol;
[0065] Its characteristic structure is:
[0066]
[0067] In the present invention, all protein structures and compound structures are from the RCSB PDB database, and the receptor module is prepared by Gromacsv2020 and AmberTools 20, and the incomplete atoms are repaired.
[0068] The embodiment of the present invention provides a compound that has a significant inhibitory or blocking effect on the VP37 protein and also has stable pharmaceutical characteristics.
[0069] The present invention constructs an in vitro molecular target model, verifies the docking center, performs molecular dynamics experiments and calculates binding energy, and finds that Formula 2 has a binding activity superior to that of the control group and a minimum binding energy. Therefore, the compound has the ability to treat monkeypox virus and smallpox virus.
[0070] The software parameter settings adopted in the present invention are all conventional settings.
[0071] A method for preparing a novel structural compound against monkeypox virus,
[0072] The method for preparing a novel structural compound for resisting monkeypox virus provided in an embodiment of the present invention comprises the following steps:
[0073] Step 1: Providing starting materials
[0074] The starting material used in the present invention is an organic compound with suitable reaction activity, and its structure is carefully selected so as to be converted into the target compound through the subsequent chemical reaction steps. The specific starting material can be selected according to actual needs, but it must be ensured that it can obtain a molecular formula of C 30 H 44 O5 target compound.
[0075] Step 2: Chemical Reaction Process
[0076] The starting materials are gradually converted into the target compound through a series of carefully designed chemical reaction steps, including but not limited to oxidation, reduction, addition, elimination, etc. In these reaction steps, the reaction conditions, such as temperature, pressure, reaction time, etc., are strictly controlled to ensure the smooth progress of the reaction and the formation of the target product.
[0077] Step 3: Use specific catalysts and solvents
[0078] In order to improve the reaction efficiency and selectivity and ensure the yield and purity of the target compound, the present invention adopts a specific catalyst or solvent in the chemical reaction step. These catalysts or solvents can effectively promote the reaction and inhibit the occurrence of side reactions, thereby improving the purity and yield of the target compound.
[0079] Step 4: Isolation and purification
[0080] After the reaction is completed, the reaction product is separated and purified. This step includes but is not limited to extraction, crystallization, recrystallization, chromatographic separation and other operations to remove impurities and obtain a novel structure compound of anti-monkeypox virus with a purity that meets the requirements of medical application. In the separation and purification process, the operating conditions also need to be strictly controlled to ensure the purity and yield of the target compound.
[0081] Then, computer-aided drug design technology was used to conduct virtual docking simulation between the target compound and VP37 protein based on the protein structure molecular docking method;
[0082] Based on the docking simulation results, design or select candidate compounds that can form stable binding with VP37 protein;
[0083] Candidate compounds are prepared and their inhibitory or blocking effects on VP37 protein are verified through experiments, thereby obtaining novel structural compounds against monkeypox virus.
[0084] The method comprises the following steps:
[0085] Step 1, molecular docking experiment
[0086] Molecular docking is a computer simulation method used to predict the interaction between small molecule compounds (such as drug candidates) and target proteins (VP37 protein in this case). Through molecular docking, candidate compounds that form stable binding with VP37 protein can be quickly screened, thus greatly narrowing the range of compounds that need further experimental verification. The binding ability of VP37 protein is improved by using binding mode and scoring function.
[0087] Step 2: Binding energy calculation experiment
[0088] A fast scoring function is used to calculate and compare different candidate compounds, rank the conformations and binding energies of these compounds, select better and lower ones for simulation experiments, and then simulate the biological environment to calculate the binding energy and compare it with the reference compound.
[0089] Step 3: Activity calculation experiment
[0090] An explicit calculation method is used to predict the inhibitory activity of the compound, which is combined with the binding energy. The compound is continuously optimized by optimizing functional groups, adjusting substituents and positions, etc., and combined with theoretical values. The calculation is better than the reference compound and further experimental design is carried out.
[0091] Prepare the novel structural compound against monkeypox virus as claimed in claim 1 or 3;
[0092] Select a pharmaceutically acceptable carrier, including but not limited to microcrystalline cellulose, lactose, magnesium stearate, etc.;
[0093] The novel structural compound against monkeypox virus is mixed with a carrier and prepared into a pharmaceutical preparation suitable for clinical use, such as tablets, capsules, oral liquid, etc., through formulation technology.
[0094] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0095] Example 1 Molecular docking experiment
[0096] Since there is no VP37 protein structure in the PDB database, the present invention uses three commonly used protein generation methods, AlphaFold2, Swiss-model and I-TASSER, to generate docking proteins. Then, according to the VP37 gene sequence of MPXV_USA_2022_MA001, the three web pages are input respectively to obtain the three protein structures.
[0097] like Figure 4 As shown in the figure, combined with the comprehensive analysis of protein stability and docking site, the docking region structure of AlphaFold2 has a high confidence interval, and relatively speaking, the confidence interval is high. Therefore, the AlphaFold2 structure was selected as the docking protein.
[0098] The GHECOM website was used to analyze the docking pockets of protein structural modules. In the docking box, the network center is defined as the docking center. The ligand small molecule is docked using the Vina mode. All other parameters are the default values in the docking module in AutoDock Vina.
[0099] According to the Chinese medicine prescription for the clinical treatment of monkeypox, it is converted into small molecule compounds. Figure 2 As shown, the structural formula of the ST-246 molecule is
[0100]
[0101] like Figure 3 As shown, the structural formula of the MOL012055 molecule is
[0102]
[0103] After sorting and scoring function analysis, it was found that compound 2 was superior to the reference compound. The results are shown in Table 1, and the score of compound 2 was lower than that of reference compound ST-246.
[0104] Table 1 Scoring results of the scoring function for compounds MOL012055 and ST-246
[0105] Score MOL012055 -9.9 ST-246 -8.1
[0106] Example 2 Molecular dynamics test
[0107] The AMBERff19SB and GAFF positions were used for both proteins and compounds, and the TIP3P water model was used for the system. The solution was treated as a cubic water box. Periodic boundary conditions (PBC) were used and 0.15 M NaCl was used to neutralize the net charge. The van der Waals interactions were calculated using the LJ 12-6 potential with a cutoff of The long-range electrostatic forces are handled using the PME algorithm. The covalent bonds involving hydrogen atoms are constrained using the SHAKE algorithm. To eliminate unfavorable interatomic contacts, the heavy atoms are first Constraints were imposed, and 2500 steps of steepest descent and 2500 steps of conjugate gradient energy minimization were performed. The entire system was then relaxed and 10,000 steps of steepest descent and 10,000 steps of conjugate gradient energy minimization were performed. The system was then gradually heated to 300K using a 20ps NVT simulation. This was followed by a two-step equilibrium phase, first a 200ps constrained heavy atom NPT simulation, followed by a 500ps unconstrained NVT simulation. The temperature was controlled at 300K using a Berendsen thermal bath, and the pressure was controlled at 1atm using a Monte Carlo pressure bath. The coupling constant and relaxation time were both 1ps. Finally, a 100ns NVT simulation was performed with an integration time step of 2fs.
[0108] The results are as follows Figure 5 It is stated that based on 100ns molecular dynamics simulation, the calculated RMSD value can indicate the stability of the interaction between the compound and the protein.
[0109] The following is a description of specific embodiments of novel structural compounds against monkeypox virus:
[0110] Example 1: Preparation of novel structural compounds against monkeypox virus
[0111] 1. Materials and Methods
[0112] Raw materials: According to the molecular formula C 30 H 44 O5, prepare corresponding chemical raw materials and reagents.
[0113] Preparation steps: Through organic synthesis methods, according to the predetermined reaction path and conditions, the raw materials are gradually converted into the target compound.
[0114] Purification: Purify the synthesized product using chromatography (such as column chromatography, thin layer chromatography, etc.) or crystallization to obtain a pure new structural compound that is anti-monkeypox virus.
[0115] 2. Verification
[0116] Through molecular dynamics simulation and protein structure virtual screening technology, the interaction between the compound and VP37 protein was verified, and its ability to inhibit or block the activity of VP37 protein was evaluated.
[0117] Example 2: Pharmaceutical application of novel structural compounds against monkeypox virus
[0118] 1. Preparation of drug preparations
[0119] The novel structural compound against monkeypox virus obtained in Example 1 is mixed with a pharmaceutically acceptable carrier.
[0120] Carrier selection: Select commonly used pharmaceutical carriers, such as microcrystalline cellulose, lactose, magnesium stearate, etc., to improve the solubility, stability or taste of the compound.
[0121] Preparation type: The drug can be prepared into different dosage forms such as tablets, capsules, oral liquids, etc.
[0122] 2. Pharmaceutical evaluation
[0123] The efficacy of the drug preparation was evaluated, and its inhibitory effect on monkeypox virus was assessed through in vitro and animal experiments.
[0124] Conduct safety evaluation of drugs, including studies on acute toxicity, long-term toxicity, and genotoxicity.
[0125] Example 4 MM / PBSA binding energy test
[0126] Binding free energy calculations were performed on the last stable 20 ns snapshot of the molecular dynamics trajectory using the MM / PBSA method in AmberTools 20. For every 100 frames, the binding free energies of the receptor, ligand, and complex were calculated using the “single trajectory” approach.
[0127] The total binding free energy was calculated according to the following formula:
[0128] ΔG bind =ΔG complex -(ΔG receptor +ΔG ligand )
[0129] =ΔE vdw +ΔE ele +ΔG PB +ΔG SA -TΔS
[0130] Among them, ΔG complex , ΔG receptor and ΔG ligand represent the free energy of the complex, receptor, and ligand, respectively; ΔE vdw , ΔE ele, ΔG PB and ΔG SA are the polar and nonpolar parts of van der Waals energy, electrostatic energy and desolvation free energy respectively; TΔS represents the conformational entropy contribution at temperature T. ΔG PB The term is determined by the PB model, and ΔG SA Then ΔG SA =γ×SASA+β, where SASA is the solvent accessible surface area, and the values of constants γ and β are and 0.92 kcal·mol-1. The molecular surface area is determined by the radius The results are shown in Table 2.
[0131] Table 2 Binding energy calculation results of MOL012055 and ST-246 compounds
[0132] <![CDATA[ΔG bind(kcal / mol) ]]> MOL012055 -18.26 ST-246 -14.89
[0133] Example 4 Based on large-scale prediction activity test
[0134] The stable conformation in AMBER docking was used to predict the binding energy of the stable structure using the PRODIGY-LIG website, and then the inhibitory activity in the stable state was obtained using the following formula (1), where R is the room temperature constant, T is the room temperature of 25 °C, and the standard temperature is 298K.
[0135] RTIn(K D )=ΔG bind
[0136] According to the webpage, the binding energy of compound ST-246 is -8.07 kcal / mol, which is lower than the binding energy of -11.79 kcal / mol of compound 2. According to the predicted activity calculated by the formula, the activity of compound 2 (0.00255 μM) is higher than the activity of compound ST-246 (1.31 μM).
[0137] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.
Claims
1. A novel structural compound for resisting monkeypox virus, characterized in that: The molecular formula of the novel structural compound against monkeypox virus is: C 30 H 44 O5, molecular weight 484.32g / mol; structural formula: 。 2. The novel structural compound against monkeypox virus according to claim 1, characterized in that: The compound is verified by molecular dynamics simulation and protein structure virtual screening technology based on the protein structure molecular docking method.
3. The novel structural compound against monkeypox virus according to claim 1, characterized in that: The compound inhibits or blocks the VP37 protein.
4. The novel structural compound against monkeypox virus according to claim 1, characterized in that: The compound includes a pharmaceutically acceptable carrier.
5. Use of the novel structural compound against monkeypox virus as claimed in any one of claims 1 to 4 in the preparation of preparations against monkeypox virus and smallpox virus.
6. A vaccine for preventing monkeypox virus, characterized in that: The invention comprises a novel structural compound against monkeypox virus as claimed in any one of claims 1 to 4.
Citation Information
Patent Citations
Application of cycloartane type triterpenoids compound of cimicifuga rhizome for anti-osteoporosis and menopausal syndrome
CN101057854A
Traditional Chinese medicine composition for resisting novel coronavirus and application thereof
CN117959388A
Therapeutic agent for bone disease containing extract of black cohosh root
JP1997030977A
